fda bpc-157 not approved peptide warning FDA's Overreach on Compounded Peptides bpc-157 fda warning safety approved

Human clinical trial activity is emerging

Pringsheim T, Davenport W, Mackie G, Worthington I, Aube M, Christie SN,

(2.2) Dosage Forms and Strengths Injection: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg per 0.5 mL in single-dose pen or single-dose vial (3) Injection: 10 mg/2.4 mL (4.17 mg/mL) for four 2.5 mg/0.6 mL doses, 20 mg/2.4 mL (8.33 mg/mL) for four 5 mg/0.6 mL doses, 30 mg/2.4 mL (12.5 mg/mL) for four 7.5 mg/0.6 mL doses, 40 mg/2.4 mL (16.7 mg/mL) for four 10 mg/0.6 mL doses, 50 mg/2.4 mL (20.8 mg/mL) for four 12.5 mg/0.6 mL doses, or 60 mg/2.4 mL (25 mg/mL) for four 15 mg/0.6 mL doses in a multi-dose vial or single-patient-use KwikPen (3) Contraindications Warnings and Precautions Acute Pancreatitis: Has been observed in patients treated with GLP-1 receptor agonists, or MOUNJARO

You can reduce weight without painful, invasive procedures

These products are not intended to diagnose, treat, cure, or preventany disease